Pfizer's RSV vaccine, Abrysvo, has shown a strong immune response and well-tolerated safety profile in new study. | The GW Vaccine Research Unit

August 14, 2024

Our Deputy Director, Dr. Elissa Malkin, was a part of the Pfizer's newest study on its respiratory syncytial virus (RSV) vaccine, Abrysvo, which has shown to have a strong immune response in adults 18+.

Check out the article for more information!

Respiratory viruses

Latest News

A needle withdraws the vaccine in an RSV vial.

FDA Approves Abrysvo for Adults 18-59 at Increased Risk for RSV

October 24, 2024

FDA Approves Abrysvo for Adults 18-59 at Increased Risk for RSV

mpox virus particles from NIAID Integrated Research Facility (credit: NIAID)

Mpox Vaccine Is Safe and Generates a Robust Antibody Response in Adolescents

October 16, 2024

Mpox Vaccine Is Safe and Generates a Robust Antibody Response in Adolescents

Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial

September 26, 2024

Latest news about the results of the COVAIL trial regarding the Sanofi booster. GW participated as one of the many sites for this COVID-19 vaccine study.